Small-scale, top-quality development capabilities
IBSA is organized so to maximise the yield from development programs. This is achieved by careful selection of the projects based on the perception of the actual clinical needs. Then, the company leverages on full availability of in-house resources for any phase of development including basic research, pharmaceutical techniques, pre-clinical and clinical research and, regulatory.
The high efficiency of the development process ensures a sustainable time-to-market as well as cost-efficiency enabling the company to be present in the market with unparalleled cost competitiveness.

All of IBSA products are manufactured in-house. Manufacturing capabilities range from oral formulations to high-tech injectables. The company is particularly specialised in the field of topical formulations leveraging on patented technologies for transdermal drug delivery.
The manufacturing sites are concentrated in Switzerland with some activities running in Italy and in China. The manufacturing facilities operate in compliance with the highest possible standards to match current regulatory requirements. Committed to improvement, IBSA manufacturing very often anticipates the developing quality standards.

In spite of its relatively small size IBSA is already actively marketing its proprietary drugs in about 50 countries in four continents. According to the territory the marketing activities are managed either by company subsidiaries or by carefully selected, high quality licensees.
Reluctant to any form of aggressive promotion, IBSA marketing activities are focused on fair information and on integrated support intended to fulfil any physician’s need relevant to its products.